{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:11:26Z","timestamp":1788754286170,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.semarthrit.2026.153042","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:12:04Z","timestamp":1783437124000},"page":"153042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune checkpoint inhibitor-associated eosinophilic fasciitis: A FAERS pharmacovigilance analysis of a rare rheumatic immune-related adverse event"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9982-0322","authenticated-orcid":false,"given":"Ze","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2026.153042_bib0001","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153042_bib0002","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153042_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.revmed.2025.05.004","article-title":"Immune checkpoint inhibitor-related eosinophilic fasciitis: 3 case reports with literature review","volume":"46","author":"Biteau","year":"2025","journal-title":"Rev Med Interne"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153042_bib0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1684\/ejd.2025.4825","article-title":"Eosinophilic fasciitis induced by immune checkpoint inhibitors successfully controlled with dapsone","volume":"35","author":"Tsuboi","year":"2025","journal-title":"Eur J Dermatol: EJD"},{"issue":"4\u20135","key":"10.1016\/j.semarthrit.2026.153042_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdin.2023.06.004","article-title":"Diagnostic imaging for eosinophilic fasciitis: a systematic review","volume":"13","author":"Chohan","year":"2023","journal-title":"JAAD Int"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153042_bib0008","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jdcr.2020.04.010","article-title":"Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression","volume":"6","author":"Bui","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0009","article-title":"Treatment and monitoring of eosinophilic fasciitis","volume":"11","author":"Selva-O'Callaghan","year":"2025","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109490","article-title":"Immune checkpoint inhibitor-induced pure red cell aplasia: case series and large-scale pharmacovigilance analysis","volume":"114","author":"Guo","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153042_bib0011","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40744-020-00246-z","article-title":"Immune checkpoint inhibitor-associated scleroderma-like syndrome: a report of a pembrolizumab-induced \"eosinophilic fasciitis-like\" case and a review of the literature","volume":"7","author":"Salamaliki","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153042_bib0012","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/ph16020259","article-title":"Checkpoint inhibitor-associated scleroderma and scleroderma mimics","volume":"16","author":"Macklin","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1613243","article-title":"Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation","volume":"16","author":"Theriau","year":"2026","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153042_bib0014","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jdcr.2020.04.017","article-title":"Eosinophilic fasciitis in association with nivolumab: the importance of eosinophilia","volume":"6","author":"Pab\u00f3n-Cartagena","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153042_bib0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.31138\/mjr.32.4.376","article-title":"Eosinophilic fasciitis following Checkpoint inhibitor therapy with Pembrolizumab","volume":"32","author":"Zampeli","year":"2021","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0016","doi-asserted-by":"crossref","unstructured":"S.H. Boppana, N.R. Dulla, B.D. Beutler, N. Gullapalli, R.J. Kaur, Drug-associated eosinophilic fasciitis: a case of eosinophilic fasciitis secondary to cemiplimab therapy, 22 (2021) e932888\u20131.","DOI":"10.12659\/AJCR.932888"},{"key":"10.1016\/j.semarthrit.2026.153042_bib0017","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153042_bib0018","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.alit.2019.03.001","article-title":"Eosinophilic fasciitis: from pathophysiology to treatment","volume":"68","author":"Ihn","year":"2019","journal-title":"Allergo J Int"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153042_bib0019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","article-title":"Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature","volume":"25","author":"Chan","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153042_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153042_bib0021","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153042_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40487-019-0096-8","article-title":"A review of immune-mediated adverse events in Melanoma","volume":"7","author":"Kennedy","year":"2019","journal-title":"Oncol Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153042_bib0023","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:00:52Z","timestamp":1788753652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S0049017226001320"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153042","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-associated eosinophilic fasciitis: A FAERS pharmacovigilance analysis of a rare rheumatic immune-related adverse event","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153042"}}